Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table reconciles reported revenues to net loss under the significant expense principle for the years ended December 31, 2024, and 2023:

	Year Ended December 31,
	2024		2023
Revenues	$	57,561	$	50,583
Costs and expenses:
Total Manufacture and Supply Expenses	17,872		20,831
R&D Project expenses:
Anaphylm project expenses	9,471		5,826
AQST-108 project expenses	786		—
Libervant project expenses	2		(887)
R&D other expenses:
Personnel costs1	7,724		6,231
Other2	2,297		1,934
Total Research and Development Expenses	20,280		13,104
Selling expenses:
Personnel costs1	2,382		864
Other3	5,164		775
Total Selling expenses	7,546		1,639
General & Administrative expenses:
Personnel costs1	21,064		10,770
Other4	21,570		19,341
Total General and Administrative Expenses	42,634		30,111
Total Selling, General and Administrative Expenses	50,180		31,750
Total costs and expenses	88,332		65,685
Loss from operations	(30,771)		(15,102)
Other (expenses) income	(13,380)		7,477
Net loss before income taxes	(44,151)		(7,625)
Income taxes benefits (expense)	14		(245)
Net loss	$	(44,137)	$	(7,870)
Comprehensive loss	$	(44,137)	$	(7,870)

1 - Personnel costs include payroll expenses, share-based compensation expenses and severance

2 - Other Research and Development expenses include preclinical, consulting, maintenance, and testing fees

3 - Other Selling expenses include commercialization and other related expenses

4 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs